SILPAK BISWAS

Dr. SILPAK BISWAS


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 February 2023 in Antibiotics
Verified
Journal Article
Open access
PDF file
MCMandira Chakraborty
Mandira Chakraborty
SSSayani Sardar
Sayani Sardar
RDRituparna De
Rituparna De
MBMalabika Biswas
Malabika Biswas
MMMaria Teresa Mascellino
Maria Teresa Mascellino
AMAnita Nandi Mitra
Anita Nandi Mitra
Nosocomial infections by multidrug-resistant (MDR) bacteria are among the main causes of morbidity and death in patients hospitalized in intensive care units (ICUs) worldwide. Antibiotic resistance has become a major concern for treating the patients with nosocomial infections. The aim of this study was to describe the antibiotic resistance patterns of pathogens causing infections in adult and pediatric patients in the ICUs of a tertiary care hospital in Kolkata, India. A cross-sectional, retrospective study was conducted from January 2022 to October 2022 on a total of 139 adult and 146 pediatric patients. Depending on clinical symptoms of the patients, samples were collected and subjected to antibiotic sensitivity testing. The culture and sensitivity pattern of clinical isolates from blood, urine, sputum, endotracheal tube (ET) aspirate, and central line catheter insertion site swabs were analyzed. A total of 695 and 556 specimens were obtained from adult and pediatric ICU, respectively. Culture positivity rate among adults and pediatric patients were 37% and 40%, respectively. The most commonly isolated organisms were Gram-negative Enterobacterales and non-fermenters. Most of the bacterial isolates showed very high resistance against multiple antibiotics. Escherichia coli from adult and pediatricpatients were found to be resistant to second generation cephalosporins (95% and 96%, respectively), beta-lactams (95% and 63%, respectively), fluoroquinolones (95% and 81%, respectively), and cotrimoxazole (85% and 78%, respectively). Klebsiella spp. from adult patients were found to be resistant to aminoglycosides (75%), second generation cephalosporins (100%), beta-lactams (94%), fluoroquinolones (92%), carbapenems (88%), and cotrimoxazole (83%). Proteus spp., Acinetobacter baumannii, and Pseudomonas spp. werefound to be resistant to multiple antibiotics. Enterococcus spp. from ICUs showed more than 90% resistance against ampicillin and more than 75% resistance against fluoroquinolones. MDR bacterial infections are increasing in both adult and pediatric ICUs, leading to significant therapeutic challenges. A frequent study of antimicrobial resistance patterns is imperative for antibiotic stewardshipin combatting the deadly effect of the MDR bacteria in critically ill patients.

13 February 2020 in Antibiotics
Verified
Journal Article
Open access
PDF file
SBSILPAK BISWAS
SILPAK BISWAS
MEMohammed Elbediwi
Mohammed Elbediwi
GGGuimin Gu
Guimin Gu
Min YueMin Yue
Min Yue
Colistin is considered to be a ‘last-resort’ antimicrobial for the treatment of multidrug-resistant Gram-negative bacterial infections. Identification of Enterobacteriaceae, carrying the transferable colistin resistance gene mcr-1, has recently provoked a global health concern. This report presents the first detection of a hydrogen sulfide (H2S)-producing Escherichia coli variant isolated from a human in China, with multidrug resistance (MDR) properties, including colistin resistance by the mcr-1 gene, which could have great implications for the treatment of human infections.

26 September 2022 in Antibiotics
Verified
Journal Article
Open access
PDF file
MBMalabika Biswas
Malabika Biswas
SBSILPAK BISWAS
SILPAK BISWAS
BGBishal Gupta
Bishal Gupta
MMMaria Teresa Mascellino
Maria Teresa Mascellino
ARAnindita Rakshit
Anindita Rakshit
BCBanya Chakraborty
Banya Chakraborty
Enteric fever, a potentially fatal multisystem disease that is caused by Salmonella enterica serovar Typhi and Paratyphi, poses a significant risk in low- and middle-income countries. A retrospective study to understand the prevalence and evolving patterns of antibiotic resistance in Salmonella Typhi and Paratyphi was undertaken from June 2017 to June 2022. A total of 4051 blood samples were collected from patients attending inpatient and outpatient departments of the School of Tropical Medicine (Kolkata, India) hospital. Blood samples were cultured, and culture positive samples were further processed for identification using conventional and automated systems. Antibiotic susceptibility test was performed using both the Kirby-Bauer disc diffusion method and VITEK2 (bioMerieux). Forty-five (1.1%) Salmonella species were isolated among the number of total (n = 4051) samples that were tested. Out of the 45 Salmonella isolates, 35 were Salmonella Typhi (77.77%) and 10 were Salmonella Paratyphi A (22.23%). We found pronounced fluoroquinolone resistance of 100% in the recent years (2019–2022) in both of the S. Typhi and S. Paratyphi A isolates. We found that 1 Salmonella Typhi and 2 Salmonella Paratyphi A isolates were resistant against multiple antibiotics (cefixime, ceftriaxone, ciprofloxacin and nalidixic acid), and 1 multidrug-resistant (MDR) Salmonella Paratyphi A isolate was found in a recent study year (2020) and it showed resistance against different classes of antibiotics (cephalosporins, fluoroquinolones and carbapenems). There was no resistance that was detected to the 3rd generation cephalosporins in the final years of the study. The emergence of Salmonella isolates that are resistant to multiple antibiotics poses a serious health problem. The antimicrobial resistance patterns that were detected in the study thus warrant further studies to understand the antibiotic susceptibility and resistance pattern of Salmonella against the major classes of antibiotics.

1 January 2025 in AIMS Microbiology
Verified
Journal Article
Open access
MCMandira Chakraborty
Mandira Chakraborty
SSSayani Sardar
Sayani Sardar
DGDebasish Ghosh
Debasish Ghosh
BSBiyanka Sau
Biyanka Sau
MMMaria Teresa Mascellino
Maria Teresa Mascellino
AMAnita Nandi Mitra
Anita Nandi Mitra
Hospital acquired infections (HAI) are the most common cause of mortality among critically ill patients because of various predisposing factors such as co-morbidities (medical or surgical), invasive devices, a long-term stay in the Intensive Care Unit (ICU), and the use of broad-spectrum empirical antibiotics. HAI in ICUs include mainly four types of infections: Catheter-related bloodstream infection (CRBSI), ventilator-associated pneumonia (VAP), catheter-related urinary tract infection (CAUTI), and surgical site infections (SSI). In this study, we aimed to characterise the bacteriological andantibiotic resistance profiles of all types of HAI along with their outcomes in the ICU of a tertiary care hospital in Eastern India. Patients included in this study were all critically ill patients aged above 12 years who had one or more devices inserted and were admitted in the ICU due to some medical or surgical complication for more than 48 hours. This was a prospective study for a period of three months. Appropriate specimens were collected from admitted patients suspected of having infections for identification and antibiotic susceptibility testing. The outcomes were determined based on either the discharge of the patient, a transfer to a separate ward, or death within the hospital. A total of 169 patients were included in the study, of which 65 patients (38%) acquired an HAI in the ICU. Thirteen patients were diagnosed with multiple types of infections. There were 72 device related infections, of which CRBSI made up 36%, VAP made up 23%, CAUTI made up 20%, and SSI made up 21% of the total patients. The most isolated organism in the ICU setup was Klebsiella spp. (35%), followed by Enterococcus spp. (22%). We found that 92% of the Klebsiella spp. was resistant to Carbapenem and 30% were Vancomycin-Resistant Enterococcus (VRE). The highest mortality was found associated with VAP (73%), followed by CRBSI (52%), SSI (40%), and CAUTI (31%) in the ICU setting. The findings of this study are of great clinical importance and will help in preventing and controlling the spread of HAIs in the ICU.